Evidence map›Paper›PMID 38138212›Full record

ArticleMedicina (Kaunas, Lithuania)2023

Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study.

Mohammed Kamal Nassar, Alaa Sabry, Mohamed Elgamal, Zeinab Zeid, Dalia Abdellateif Abdelghany, Samar Tharwat

Open access · goldAbstract readControlled Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Mohammed Kamal NassarMansoura Nephrology & Dialysis Unit (MNDU), Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Alaa SabryMansoura Nephrology & Dialysis Unit (MNDU), Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Mohamed ElgamalChest Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Zeinab ZeidAl-Khezam Dialysis Center, Al-Adan Hospital, Hadiya 47000, Kuwait.
Dalia Abdellateif AbdelghanyChest Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Samar TharwatDepartment of Internal Medicine, Faculty of Medicine, Horus University, New Damietta 34517, Egypt.ORCID 0000-0001-9892-2449
Mansoura University · EGDamietta University · EGAdan Hospital · KW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Drug-Related Side Effects and Adverse ReactionsKidney Failure, ChronicAdultAntibodies, MonoclonalAntibodies, NeutralizingCOVID-19 VaccinesDrug CombinationsHumansRenal DialysisSARS-CoV-2Antibodies, MonoclonalAntibodies, Neutralizingcilgavimabcilgavimab and tixagevimab drug combinationCOVID-19 VaccinesDrug CombinationstixagevimabcilgavimabEvusheldhemodialysistixagevimab

Identifiers

PMID38138212
PMCPMC10744812
OpenAlexW4389246913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.